Galapagos

AZ, BioFocus, Argenta collaborate on respiratory and inflammatory diseases

Thursday, March 15, 2012 06:02 AM

Galapagos’ service companies, BioFocus and Argenta, have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets in respiratory and inflammatory diseases.

More... »


Abbott and Galapagos collaborate on autoimmune diseases

Friday, March 2, 2012 07:39 AM

Abbott and Galapagos, a biotechnology company based in Belgium, have entered into a global collaboration to develop and commercialize an oral, next-generation JAK1 inhibitor (GLPG0634) in phase II development with the potential to treat multiple autoimmune diseases.

More... »


Almirall and Galapagos enter into research alliance

Friday, January 27, 2012 01:57 PM

Barcelona, Spain-basedAlmirall has formed a research alliance with BioFocus, an affiliate of Galapagos. The three-year collaboration is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. 

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs